Protagonist Therapeutics
PTGX
275 hedge funds and large institutions have $3.15B invested in Protagonist Therapeutics in 2025 Q1 according to their latest regulatory filings, with 71 funds opening new positions, 87 increasing their positions, 90 reducing their positions, and 35 closing their positions.
103% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 35
100% more funds holding in top 10
Funds holding in top 10: 7 → 14 (+7)
60% more call options, than puts
Call options by funds: $51.1M | Put options by funds: $31.9M
29% more capital invested
Capital invested by funds: $2.44B → $3.15B (+$708M)
14% more funds holding
Funds holding: 241 → 275 (+34)
0.29% more ownership
Funds ownership: 106.16% → 106.46% (+0.29%)
3% less repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 90
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$83.8M |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$30.7M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$28.3M |
| 4 |
NVCHI
New Vernon Capital Holdings II
Morristown,
New Jersey
|
+$14.5M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$14.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$72.4M |
| 2 |
JFG
Jefferies Financial Group
New York
|
-$35.9M |
| 3 |
State Street
Boston,
Massachusetts
|
-$26.2M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$15.1M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$13.5M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VEA
301
Virtus ETF Advisers
New York
| – | -$68K | -1,761 | Closed |
|
|
FIA
302
FNY Investment Advisers
New York
| – | -$38K | -1,000 | Closed |
|
|
HFM
303
Harvest Fund Management
Beijing,
China
| – | -$3K | -80 | Closed |
|
304
Group One Trading
Chicago,
Illinois
| – | -$2.93K | -70 | Closed |
|
|
AAP
305
Arax Advisory Partners
Denver,
Colorado
| – | -$811 | -21 | Closed |
|
306
Jones Financial Companies
Des Peres,
Missouri
| – | -$695 | -18 | Closed |
|
307
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$270 | -7 | Closed |
|
|
HNB
308
Huntington National Bank
Columbus,
Ohio
| – | -$193 | -5 | Closed |
|
|
IA
309
IFP Advisors
Tampa,
Florida
| – | -$193 | -5 | Closed |
|
|
HFS
310
Hantz Financial Services
Southfield,
Michigan
| – | +$84 | +2 | New |
|
PTGX Hedge Fund Activity: Q1 2025 in Review
275 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q1 2025, worth a combined $3.15B — up 29% from $2.44B a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new PTGX positions and 35 closed out — a net gain of 36 holders — while 87 added to existing stakes and 90 trimmed.
The largest buyer was Deep Track Capital, adding an estimated $83.8M. The largest seller was Pacer Advisors, exiting entirely with an estimated $72.4M sold.
- 275 institutional investors held Protagonist Therapeutics (PTGX) as of Q1 2025, up from 241 in Q4 2024.
- Funds reported $3.15B of Protagonist Therapeutics stock for Q1 2025, up 29% quarter-over-quarter.
- 71 funds opened new Protagonist Therapeutics positions in Q1 2025 and 35 closed out, a net change of +36 holders.
- The largest Protagonist Therapeutics buyer in Q1 2025 was Deep Track Capital, an estimated $83.8M added.
- The largest Protagonist Therapeutics seller in Q1 2025 was Pacer Advisors, an estimated $72.4M sold.
Based on aggregated 13F filings for Q1 2025.